OpGen, Inc. (NASDAQ:OPGN) Sees Large Decrease in Short Interest

OpGen, Inc. (NASDAQ:OPGN) was the target of a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 164,100 shares, a drop of 92.6% from the March 31st total of 2,230,000 shares. Based on an average trading volume of 1,650,000 shares, the short-interest ratio is currently 0.1 days. Approximately 1.4% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of OpGen in a research report on Monday. They issued a “sell” rating on the stock.

OpGen Price Performance

NASDAQ OPGN traded down $0.03 during mid-day trading on Thursday, hitting $0.53. The company’s stock had a trading volume of 195,649 shares, compared to its average volume of 1,387,221. OpGen has a 52-week low of $0.17 and a 52-week high of $3.84. The stock’s fifty day simple moving average is $0.57 and its two-hundred day simple moving average is $0.51. The firm has a market capitalization of $6.71 million, a P/E ratio of -0.08 and a beta of -0.71.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.